作为线粒体调节器的配体修饰金纳米颗粒:肠道屏障的调节和便秘治疗
Wenshuai Hao1,2, Ruitao Cha2, Mingzheng Wang2
1Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid Wastes, National Laboratory of Mineral Materials, School of Materials Science and Technology, China University of Geosciences (Beijing), Beijing 100083, P. R. China.
ACS nano
|July 14, 2023
概括
用4,6-胺-2-胺基尼醇 (D-Au NPs) 修改的金纳米颗粒可以增强肠道线粒体功能. 这改善了细胞平衡和屏障完整性,为治疗便秘等代谢性肠道疾病提供了潜力.
科学领域:
- 生物医学工程 生物医学工程
- 线粒体生物学 线粒体生物学
- 胃肠病学 胃肠病学
背景情况:
- 肠道线粒体功能障碍与便秘,IBD,IBS和结直肠癌等代谢疾病有关.
- 肠道上皮细胞中的线粒体对于运动性和新陈代谢至关重要.
- 改善线粒体功能是预防和治疗这些疾病的关键.
研究的目的:
- 为了研究4,6-米诺-2-米丁乙醇改性金纳米颗粒 (D-Au NPs) 对肠道线粒体的影响.
- 探索D-Au NPs在线粒体代谢相关疾病中的调节作用.
主要方法:
- 用D-AuNP进行治疗.
- 对线粒体抗氧化能力的评估.
- 分析通过AMPK,PGC-1α,UCP2和DRP1信号传递来调节线粒体代谢.
- 对肠道机械屏障功能的评估.
主要成果:
- D-Au NPs增强了线粒体的抗氧化.
- D-Au NPs通过激活AMPK和PGC-1α信号来调节线粒体新陈代谢.
- 这些效应改善了肠道细胞平衡和机械屏障.
- 在预防便秘方面,D-Au NPs干预显示出有效性.
结论:
- D-Au NPs可以改善肠道线粒体功能.
- 这种改善有助于维持肠道细胞平衡和屏障完整性.
- D-Au NPs代表了线粒体代谢相关的肠道疾病的潜在治疗策略.
更多相关视频
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
219
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
219
Drugs Affecting GI Tract Motility: Other Laxatives
280
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
280
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
252
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
252
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
247
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
247
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
313
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
313


